H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of $107, up from $90, after Merck said it will acquire Verona for $107 per American depository share. The firm does not expect any competitors to attempt to outbid Merck.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Neutral from Overweight at Piper Sandler
- Verona Pharma downgraded to Hold from Buy at Truist
- Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research
- Verona Pharma downgraded to Neutral from Buy at Roth Capital
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal